Zimbabwe has rejected a substantial American healthcare agreement worth $367m (272 million pounds) spanning five years because of the United States' demand for sensitive information.
The decision became public after a government memo from December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the arrangement was "lopsided".
A government spokesperson has since explained that the US was demanding access to health data for scientific study and commercial purposes while was unwilling to share the resulting advantages from future medical innovations.
"We are forced to start the challenging and unfortunate process of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had provided more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for further dialogue to secure a deal agreeable to all parties so the nation's vital HIV treatment initiative can continue.
Broader Context
Zimbabwe's decision comes after a similar situation in Kenya, where a court suspended a similar health funding agreement following concerns were filed about the security of Kenyans' medical information.
After resuming the presidency last year, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
The agency had managed assistance for the US government, but Trump claimed its spending was "inefficient" and his government was pursuing government-to-government agreements to enhance openness and responsibility.
Based on statements, 16 African countries have so far signed similar agreements, constituting over $18.3bn in new funding.
Details of the Declined Agreement
This assistance for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership could have provided significant benefits for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy via American-funded programmes," Tremont commented.
However, government spokesperson Nick Mangwana said the proposed deal was "unfair".
"The proposal required Zimbabwe to surrender its biological resources and data over an extended period, with no corresponding guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that could be developed from that shared data," his statement read.
"Put simply, our country would supply the basic resources for scientific discovery without any certainty that the resulting innovations would be available to our citizens should a new pandemic arise."
Sovereignty and Global Health
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were undermining frameworks already set up via the international health agency.
The spokesperson cited its Pandemic Benefit-Sharing framework created to deal with future pandemics.
"This mechanism is intended to guarantee that when a nation provides its data, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the capability to create them."
These objections over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We welcome ongoing discussions with our US partners on how subsequent co-operation could be designed in a way that honours the sovereignty and interests of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the government's concerns, but suggested that negotiations need to persist considering much of the nation's HIV programmes depended on foreign aid.
"Where technical issues arise, such as those involving data governance or agreement terms, these can often be addressed via technical clarification and negotiated safeguards," the group commented.
The halted deal underscores the complex tensions between receiving vital foreign assistance and protecting a country's data in an ever more data-driven world.